Question · asked by 1 review

IVIg vs placebo or no treatment: Event‐free survival (no death, transplant, or left ventricular assist device) ‐ adults with myocarditis

It is very uncertain whether intravenous immunoglobulin changes event‐free survival (risk of death, cardiac transplant, or left… compared with placebo or no treatment (very low certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Intravenous immunoglobulin vs placebo or no treatment
Event‐free survival (risk of death, cardiac transplant, or left ventricular assist device) ‐ adults with myocarditis, median · adults with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes event‐free survival (risk of death, cardiac transplant, or left… compared with placebo or no treatment (very low certainty).
Intravenous immunoglobulin for presumed viral myocarditis in children and adults (2020) · Cochrane Headline outcomes only
RR 1.76 [0.48, 6.4]1 study · 62 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Intravenous immunoglobulin for presumed viral myocarditis in children and adults
2020 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.